BDBM562769 (2-((2S,5R,6S)-6-(3-Chlorophenyl)-5-(4-chlorophenyl)-4-(cyclopropylmethyl)-3-oxomorpholin-2-yl)acetaldehydeacetaldehyde and (2-((2R,5S,6R)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-4-(cyclopropylmethyl)-3-oxomorpholin-2-yl)acetaldehydeacetaldehyde::US11407721, Example 15

SMILES Clc1ccc(cc1)[C@H]1[C@H](O[C@H](CC=O)C(=O)N1CC1CC1)c1cccc(Cl)c1

InChI Key InChIKey=CYSOHQCKGNQBDC-UHFFFAOYSA-N

Data  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 562769   

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandChemical structure of BindingDB Monomer ID 562769BDBM562769(US11407721, Example 15 | (2-((2S,5R,6S)-6-(3-Chlor...)
Affinity DataIC50: 3.32E+3nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandChemical structure of BindingDB Monomer ID 562769BDBM562769(US11407721, Example 15 | (2-((2S,5R,6S)-6-(3-Chlor...)
Affinity DataIC50: 3.96E+3nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
US Patent